Here’s Who Owns Jounce Therapeutics, Inc. (JNCE)

Jounce Therapeutics, Inc. (NASDAQ:JNCE) reached 75.56% versus a 1-year low price of $2.66. The stock was last seen 2.86% higher, reaching at $4.67 on 01/10/2019. At recent session, the prices were hovering between $4.45 and $4.69. This company shares are 167.67% off its target price of $12.5 and the current market capitalization stands at $134.68M. The recent change has given its price a 12.97% lead over SMA 50 and -84.03% deficit over its 52-week high. The stock witnessed 20.36% gains, -29.88% declines and -42.49% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found JNCE’s volatility during a week at 8.98% and during a month it has been found around 9.66%.

Jounce Therapeutics, Inc. (JNCE) Top Holders

Institutional investors currently hold around $123 million or 77.4% in JNCE stock. Look at its top three institutional owners. Trv Gp Ii, Llc owns $46.45 million in Jounce Therapeutics, Inc., which represents roughly 34.49% of the company’s market cap and approximately 37.76% of the institutional ownership. Similar statistics are true for the second largest owner, Trv Gp Iii, Llc, which owns 3,048,780 shares of the stock are valued at $13.84 million. The third largest holder is Fmr Llc, which currently holds $10.01 million worth of this stock and that ownership represents nearly 7.43% of its market capitalization.

Jounce Therapeutics, Inc. 13F Filings

At the end of September reporting period, 46 institutional holders increased their position in Jounce Therapeutics, Inc. (NASDAQ:JNCE) by some 2,323,400 shares, 32 decreased positions by 2,712,508 and 20 held positions by 22,011,568. That puts total institutional holdings at 27,047,476 shares, according to SEC filings. The stock grabbed 16 new institutional investments totaling 1,000,549 shares while 14 institutional investors sold out their entire positions totaling 316,316 shares.

Jounce Therapeutics, Inc. (NASDAQ:JNCE) Insider Trades

Multiple company employees have indulged in significant insider trading. Jounce Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Chief Business Officer Cole Hugh M has acquired 1,900 shares of Jounce Therapeutics, Inc. (JNCE) in trading session dated Jun. 15, 2018. These shares are worth $14,896 and were traded at $7.84 each. The SEC filing shows that Duncan Barbara Gayle performed a sale of 2,000 shares. The Director disposed these shares by way of transaction on Mar. 15, 2018. The company’s shares were given away at $28.11 per share worth to an income of some $56,220 on account of Duncan Barbara Gayle.

CFO and Treasurer, Drapkin Kimberlee C, sold 5,267 common shares of Jounce Therapeutics, Inc. (JNCE) in the open market. In a transaction dated Mar. 08, 2018, the shares were put up for sale at an average price of $25.01, raking in a sum of $131,728. After this sale, common shares of JNCE are directly owned by the insider, with total stake valued at $.

In the transaction dated Mar. 08, 2018, the great number of shares disposed came courtesy the CEO and President; Murray Richard /Ca/ disposed a total of 16,334 shares at an average price of $25.1, amounting to approximately $409,983. The insider now directly owns shares worth $.

Jounce Therapeutics, Inc. (JNCE) Analyst Guide

Several analysts have released their opinion on Jounce Therapeutics, Inc. (NASDAQ:JNCE), with 1 analysts believing it is a strong buy. Whereas 2 of them predict the stock is a hold. Also, there are 2 buy, 1 sell and 0 strong sell ratings, collectively assigning a 2.5 average brokerage recommendation.